EMA Approves ViiV Healthcare’s Rukobia for Multidrug-Resistant HIV

The European Medicines Agency has handed ViiV Healthcare marketing authorization for Rukobia (fostemsavir) for treating multidrug-resistant HIV-1 infection.

Rukobia is now approved in Europe for use alongside other antiretroviral drugs in treating adults with multidrug-resistant HIV when other suppressive anti-viral regimens are not possible. The drug is an HIV attachment inhibitor that targets the first step of the virus’ lifecycle.

ViiV Healthcare is majority owned by GlaxoSmithKline, but Pfizer and Shionogi also hold shares in the company.